Gilead Sciences, Inc.

(NASDAQ Global Select)

Top News rankings and signal summaries are processed using AI and may contain errors.

1
Bullish +75

GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE

AI-generated analysis

Gilead Sciences and Lakefront Biotherapeutics have completed the acquisition of Ouro Medicines for a total upfront payment of $1,675 million, with Gilead and Lakefront splitting the cost equally. The deal is designed to expand Gilead's inflammation pipeline by adding gamgertamig (OM336), a clinical-stage BCMAxCD3 T...

Bullish Signals

  • Gilead acquires Ouro Medicines for $1,675M plus up to $500M milestones.
  • Gamgertamig (OM336) is FDA Fast Track/Orphan Drug designated T cell engager.
  • Registrational studies expected as early as 2027 for severe antibody-mediated diseases.
  • Lakefront receives 20%–23% tiered royalties on gamgertamig net sales.
  • Lakefront gains $500M cash relief enabling up to $150M share buybacks.

Bearish Signals

  • $1.675B upfront payment strains liquidity and impacts priorities.
  • Gilead shares $1.675B cost but lacks global commercial rights.
  • $500M contingent milestones add financial exposure and liability.
  • 20-23% royalties reduce Gilead's total commercial upside.
  • Regulatory approval timing and outcomes remain unpredictable.
  • Business integration risks threaten expected acquisition benefits.
  • Clinical trial failures could force asset write-downs.
  • Regulatory limitations may restrict gamgertamig use or withdraw it.
  • Pipeline advancement and commercialization success are uncertain.
2
Bullish +65

Gilead Sciences (GILD) Q3 2026 Earnings

Earnings report Guidance raised AI-generated analysis

Gilead Sciences reported third-quarter fiscal 2026 earnings on October 29, 2026, significantly beating analyst expectations with non-GAAP EPS of $2.55 versus a consensus of $2.21 and revenue of $8.3 billion against an estimate of $7.8 billion. This performance extended the company's streak of exceeding EPS...

Bullish Signals

  • Non-GAAP EPS hit $2.55, beating estimates by 15.6%.
  • Revenue reached $8.3B, up 6.8% YoY driven by HIV sales.
  • Lenacapavir PrEP generated $305M, nearly doubling prevention revenues.
  • Product sales excluding Veklury grew 16% to $8.20B.
  • Raised full-year 2026 guidance to $31.0–$31.3 billion.
  • Gross margin expanded to 81.0% non-GAAP.

Bearish Signals

  • GAAP EPS fell to $1.94 due to higher expenses and equity losses.
  • Acquired IPR&D charges of $12.4B project a full-year loss of $(4.05).
  • Cell therapy revenues declined 18% due to sector competitive headwinds.
  • Veklury revenues dropped 69% as lower COVID hospitalizations reduced demand.
3
Bullish +65

Why is Arcellx stock up 80% today? Gilead's $7.8B answer

AI-generated analysis

Gilead Sciences has agreed to acquire Arcellx in an all-cash deal valued at approximately $7.8 billion, marking a significant strategic expansion into the cell therapy space. The transaction is structured as a tender offer followed by a merger, with Gilead already holding an 11.5% stake...

Bullish Signals

  • Acquired Arcellx for $7.8B to expand cell therapy market.
  • Targets $6B sales milestone in multiple myeloma CAR-T.
  • Deal accretive to EPS starting 2028 assuming FDA approval.
  • Consolidates collaboration since 2022, reducing integration risk.
  • FDA decision on anito-cel expected by Dec 23, 2026.

Bearish Signals

  • Stock dipped 1% after $7.8B Arcellx acquisition announcement.
  • Acquired asset faces intense competition in CAR-T category.
4
Bullish +65

GILD Surges: Trodelvy's Approval Could Transform Oncology!

AI-generated analysis

Gilead Sciences (NASDAQ: GILD) saw its stock price surge following FDA approval for Trodelvy in hormone receptor positive/HER2-negative metastatic breast cancer, marking the drug's third indication and a significant milestone as the first Trop-2 targeting ADC to show overall survival benefit in this specific patient...

Bullish Signals

  • FDA approved Trodelvy for breast cancer, first Trop-2 ADC with overall survival benefit.
  • Onco sales surged 37% YoY in 2023, validating strategic pivot to cancer therapies.
  • Generated $8.0B operating cash flow in 2023, covering dividends twice over.
  • Paid $4.0B to shareholders in 2023 via dividends and buybacks.
  • Holds $8.4B cash with net debt-to-EBITDA near 2x for R&D flexibility.
  • Interest coverage at 7x pre-tax earnings ensures comfortable obligation meeting.
  • Morningstar rates GILD a 5-star buy with wide moat and 30% undervaluation.
  • HIV franchise provides durable cash flow foundation while oncology pipeline ramps.

Bearish Signals

  • 67% revenue reliance on HIV franchise facing early 2030s patent cliffs.
  • Peak sales limited to $600M due to Enhertu competition in breast cancer.
  • EVOKE-01 trial failure for lung cancer hinders pipeline expansion beyond approved uses.
  • $21B Immunomedics acquisition risks stock if Trodelvy misses multi-billion dollar targets.
  • Increased leverage from acquisitions strains balance sheet and may trigger credit downgrades.
5
Somewhat Bullish +50

Gilead Sciences Balances Strong Growth With EPS Hit

AI-generated analysis

Gilead Sciences (GILD) reported mixed results for its Q1 earnings call, highlighting strong operational growth that was counterbalanced by significant non-recurring charges and unusual tax effects dragging reported earnings per share into the red. The company delivered total product sales of $6.9 billion, representing a...

6
Very Bullish +85

Gilead Sciences's Q1 2026 Earnings: What to Expect - Yahoo Finance

AI-generated analysis

Gilead Sciences, Inc., based in Foster City, California, is a leading biopharmaceutical company with a market capitalization of $173 billion. The firm specializes in developing medicines for unmet medical needs globally and offers a portfolio including Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and Yeztugo for...

Bullish Signals

  • EPS of $1.86 beat forecasts; revenue hit $7.9B.
  • Exceeded expectations in three of last four quarters.
  • 2026 EPS projected at $8.66, up 6.3% from 2025.
  • 2027 EPS forecasted at $9.63, up 11.2% YoY.
  • Stock rose 26.1% vs S&P 500's 16.4% gain in 52 weeks.
  • Analysts rate stock 'Strong Buy' with 22 of 32 recommending it.
  • Average price target $158.86, implying 14.2% upside.

Bearish Signals

  • Missed EPS estimates in 1 of last 4 quarters.
  • Mixed analyst sentiment with 'Hold' ratings suggested.
  • 2026 revenue of $8.45-$8.85 faces market pressure.
  • High price volatility from single earnings releases.
  • Heavy HIV-1 reliance risks patent cliff exposure.
7
Bullish +70

Gilead Sciences: The Market Is Underestimating Its Growth Runway (NASDAQ:GILD) - Seeking Alpha

AI-generated analysis

Gilead Sciences (GILD) is presented as a compelling long-term value opportunity following a recent stock pullback, with the author reaffirming a 'Buy' rating. The article highlights that the company's core HIV franchise remains robust, driving 72% of total sales, primarily through the blockbuster drug Biktarvy...

Bullish Signals

  • Management raised 2026 revenue guidance to 5.5% midpoint.
  • HIV franchise drives 72% of sales with robust growth.
  • Strong A- rated balance sheet with low leverage.
  • Offers 2.65% dividend yield for income-focused investors.
8
Bullish +75

Gilead Sciences and Lakefront complete acquisition of Ouro Medicines

AI-generated analysis

Gilead Sciences, Inc. and Lakefront Biotherapeutics NV have announced the successful completion of their acquisition of Ouro Medicines for $1.68 billion in upfront equity, with an additional potential of up to $500 million in contingent milestone payments. This transaction adds gamgertamig (OM336), a clinical-stage BCMAxCD3...

Bullish Signals

  • Gilead acquires Ouro Medicines for $1.68B plus up to $500M milestones.
  • OM336 holds FDA Fast Track and Orphan Drug Designations for rare diseases.
  • Gamgertamig targets registrational studies by 2027 for severe antibody-mediated orphan diseases.
  • Lakefront earns 20%–23% tiered royalties on gamgertamig net sales from Gilead.
  • Lakefront gains $500M cash relief, enabling buybacks and strategic transactions.
  • Lakefront expects €2B year-end 2026 cash for additional liquidity.

Bearish Signals

  • Gilead paid $1.68B upfront plus $500M milestones.
  • Significant capital outlay impacts liquidity or leverage.
9
Bullish +75

Gilead Sciences, Inc.: Gilead Sciences and Lakefront Biotherapeutics Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline

AI-generated analysis

Gilead Sciences and Lakefront Biotherapeutics have completed the acquisition of Ouro Medicines to advance T cell engager therapies for autoimmune diseases. The deal involves Gilead acquiring all outstanding equity of Ouro Medicines for $1,675 million plus up to $500 million in contingent milestone payments, with...

Bullish Signals

  • Gilead acquires Ouro Medicines for $1.675B plus up to $500M milestones.
  • Deal adds gamgertamig (OM336) with FDA Fast Track and Orphan Drug Designation.
  • Gamgertamig enters registrational studies as early as 2027 for autoimmune diseases.
  • Lakefront receives tiered royalties of 20%-23% on net sales of gamgertamig.
  • Transaction enables Lakefront to deploy at least $500M cash independently.
  • Lakefront's year-end 2026 cash balance expected to be approximately €2B.
  • Gilead invests $32 billion in 2025 to strengthen U.S. footprint and discovery.
  • Gilead operates in more than 35 countries worldwide for broad global reach.

Bearish Signals

  • $1.675B+ acquisition strains liquidity and impacts other priorities.
  • Lakefront limited to 20%-23% royalties; Gilead keeps global rights.
  • Gamgertamig studies start 2027, delaying commercialization returns.
  • Risks include failed integration and benefits not materializing.
  • Regulatory approval and trial results remain uncertain.
10
Bullish +65

Gilead Sciences stock gains fresh support from HIV prevention data

Clinical trial results Drug approval AI-generated analysis

Gilead Sciences received fresh positive data from its Phase 2 PURPOSE 5 study, presented ahead of the HIV Glasgow 2026 congress. The trial compared twice-yearly injectable lenacapavir against daily oral emtricitabine/tenofovir disoproxil fumarate (F/TDF) for HIV pre-exposure prophylaxis in patients in the UK and France...

Bullish Signals

  • 85.6% adherence in Phase 2 PURPOSE 5 study vs 46.3% for oral F/TDF.
  • Zero HIV acquisitions in lenacapavir group validates long-acting injectable prevention strategy.
  • Clinical evidence strengthens portfolio by addressing daily oral regimen adherence constraints.
11
Bullish +65

Gilead Sciences stock gets new Livdelzi Phase 3 evidence

Clinical trial results Regulatory submission AI-generated analysis

Gilead Sciences announced positive Phase 3 IDEAL study results for its drug Livdelzi in patients with primary biliary cholangitis (PBC). The trial evaluated the treatment in adults with moderately elevated alkaline phosphatase levels who had either failed ursodeoxycholic acid therapy or could not tolerate it....

Bullish Signals

  • IDEAL study showed 75.4% response rate vs 16.1% placebo.
  • Livdelzi data expands liver disease pipeline and supports regulatory talks.
  • Stock rose 1.75% to 157.27 euros on new clinical evidence.
12
Bullish +65

Gilead’s HIV Prevention Business Just Topped $1 Billion A Quarter. What Comes Next?

Company update Drug approval AI-generated analysis

Gilead Sciences (GILD) has achieved a major milestone in its HIV prevention business, with PrEP sales crossing $1 billion for the first time in a single quarter during fiscal Q2 2026. This segment, which includes medicines taken by virus-negative individuals to prevent infection, doubled from...

Bullish Signals

  • HIV prevention sales exceeded $1B in fiscal Q2 2026.

Bearish Signals

  • Sales vs. IQVIA data gap widens, raising alignment concerns.
13
Bullish +55

Gilead Sciences stock falls 1.11 percent despite revenue growth

Dividend Earnings report AI-generated analysis

Gilead Sciences reported second-quarter 2026 revenue of USD 7.80 billion, representing a 10 percent increase from the prior-year quarter and surpassing analyst consensus estimates. This growth was driven primarily by HIV product sales, which rose 12 percent to USD 5.69 billion, while cell-therapy sales declined...

Bullish Signals

  • Q2 revenue hit $7.8B, beating estimates with +12% HIV sales growth.

Bearish Signals

  • Cell-therapy sales fell 14% to USD 417 million.
  • Adjusted EPS was a loss of USD 6.75.
  • Stock fell 1.11% amid earnings volatility.
14
Somewhat Bullish +30

Gilead Sciences stock slips as earnings estimates shift

Analyst upgrade Dividend Earnings report AI-generated analysis

Gilead Sciences reported quarterly revenue of USD 7.80 billion for the period ending in September 2026, representing a 10.6 percent year-over-year increase. This sales figure significantly exceeded analyst consensus estimates by USD 400 million, with the company closing at USD 149.56 on the Nasdaq. Despite...

Bullish Signals

  • Revenue beat estimates by $400M at $7.80B.
  • EPS of -$6.75 was $0.50 better than consensus.
  • Declared quarterly dividend of $0.82 per share.
  • Analyst raised 2026 EPS forecast to -$0.44.

Bearish Signals

  • Stock fell 0.7% despite revenue growth.
  • Shares remain 4.9% below 52-week high of $157.29.
15
Bullish +52

Gilead Sciences stock holds near 52-week high as HIV prevention deal and analyst optimism support valuation

AI-generated analysis

Gilead Sciences stock closed at USD 150.11 on September 18, 2026, trading near the top of its 52-week range and reflecting a robust year-to-date gain of 22.3 percent from the start of 2026. The company's market capitalization reached approximately USD 186.12 billion as of September...

Bullish Signals

  • Stock closed at USD 150.11, up 22.3% year-to-date.
  • Analysts see upside with average target of USD 158.
  • HIV portfolio including lenacapavir drives future growth.
  • Secured agreement to expand lenacapavir access in Latin America.

Bearish Signals

  • Growth cautious due to HIV market competition and pricing limits.
  • Stock trades 17.7% above fair value, limiting upside.
16
Bullish +75

Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC Study

AI-generated analysis

Gilead Sciences and its partner Merck announced positive Phase III data from the ISLEND-1 and ISLEND-2 studies evaluating a once-weekly oral HIV treatment regimen combining islatravir and lenacapavir. Both trials met their primary efficacy endpoint at week 48, demonstrating non-inferior efficacy compared to Biktarvy in...

Bullish Signals

  • Gilead/Merck Phase III HIV studies ISLEND-1/2 met primary endpoints at week 48.
  • Regimen showed non-inferior efficacy vs Biktarvy and standard daily oral therapies.
  • Could become first weekly-dosing long-acting oral HIV treatment if approved.
  • Gilead shares gained 2.2% YTD vs industry decline of 3.1%.
  • FDA approved lenacapavir (Yeztugo) for prevention in 2025 with $1B 2026 sales.

Bearish Signals

  • Gilead/Merck discontinued KEYNOTE-D46/EVOKE-03 due to low OS benefit likelihood.
  • Trodelvy+Keytruda showed only non-significant PFS improvement vs Keytruda alone.
  • Gilead faces competition from Cabenuva/Apretude in HIV franchise market.
17
Bullish +75

Gilead Sciences (GILD), Lakefront Biotherapeutics Acquire Ouro Medicines to Advance Autoimmune Pipeline

AI-generated analysis

On June 4, 2026, Gilead Sciences (GILD) and Lakefront Biotherapeutics completed the acquisition of Ouro Medicines to advance their inflammation and immunology pipelines. The deal centers on gamgertamig (OM336), a clinical-stage T cell engager developed as a potential first-in-class treatment for severe autoimmune diseases such...

Bullish Signals

  • Gilead acquires Ouro Medicines to bolster inflammation and immunology pipelines.
  • Deal grants sole global rights for gamgertamig in autoimmune diseases.
  • Lakefront secures three preclinical programs with future profit-sharing opt-in.
  • Lakefront projects ~€2 billion cash balance by end of 2026.
  • Acquisition aligns with Gilead's durable immune reset strategic objective.
18
Bullish +70

GILD Q1 Deep Dive: HIV Growth, Oncology Pipeline, and Margin Management Shape 2026 Outlook

AI-generated analysis

Gilead Sciences (NASDAQ: GILD) reported first-quarter 2026 financial results that exceeded Wall Street expectations in both revenue and earnings per share, though the company issued revised full-year guidance reflecting significant upcoming costs. Revenue for Q1 reached $6.96 billion, a 4.4% year-over-year increase compared to analyst...

Bullish Signals

  • Q1 Revenue hit $6.96B, beating estimates by 1.5%.
  • Non-GAAP EPS reached $2.03, up 6.3% vs consensus.
  • Full-year guidance raised to $30.2B at the midpoint.
  • Operating margins expanded to 37.2%, up from 33.5%.
  • HIV segment grew 10% YoY driven by Biktarvy.
  • Oncology franchise gains momentum with Trodelvy up 37%.
  • Libdelzi sales tripled in primary biliary cholangitis treatment.
  • Acquisitions add novel assets to oncology and inflammation.
  • Margins improved via expense management and royalty expirations.
  • New launch Biclen targets virally suppressed patients.

Bearish Signals

  • Gilead lowered full-year EPS guidance to -$0.85 midpoint due to acquisition charges.
  • GAAP margin lags non-GAAP of 47% amid integration costs and upfront payments.
  • Libtelzi sales fell 11% sequentially due to inventory drawdown and post-bolus normalization.
  • Policy pricing headwinds may offset future growth in HIV and oncology segments.
  • New therapy success from Tubulis and Arcellx introduces significant execution risk.
  • Regulatory delays for Trodelvy could stall revenue ramp into 2027 and beyond.
19
Bullish +75

KYMR Q1 Earnings Top Estimates, Revenues Gain on GILD Collaboration

AI-generated analysis

Kymera Therapeutics (KYMR) reported first-quarter 2026 earnings that surpassed analyst expectations, driven largely by significant revenue growth from its collaboration with Gilead Sciences (GILD). The company posted a loss of 71 cents per share compared to a Zacks Consensus Estimate of a loss of 89...

Bullish Signals

  • Kymera Therapeutics posted Q1 earnings that topped estimates with a loss of 71 cents per share, which is narrower than the consensus estimate of 89 cents.
  • Quarterly revenues surged to $34.37 million, representing a 55.5% year-over-year increase and surpassing the Zacks Consensus Estimate of $11 million.
  • The company's partnership with Gilead Sciences (GILD) was a primary driver of revenue, resulting in a fully recognized upfront payment that sets the stage for milestone-driven variability.
  • Management received a decision from Gilead to exercise its option to exclusively license KT-200, triggering an expected $45 million milestone payment receivable in Q2 and eligibility for roughly $700 million in additional milestones.
  • Kymera exited the quarter with $1.55 billion in cash, cash equivalents, and investments, providing a supported operating runway into 2029.
  • The FDA granted Fast Track designation to KT-621 for moderate-to-severe eosinophilic asthma, complementing its existing Fast Track status in atopic dermatitis.
  • Year to date, KYMR shares gained 5.3% against the industry's 1.1% decline, outperforming peers despite market headwinds.
  • KT-621 is advancing in two parallel Phase IIb trials in dermatology and respiratory indications with enrollment expected to be completed in 2026.

Bearish Signals

  • Kymera Therapeutics reported a net loss of 71 cents per share in Q1 2026, which, while better than the consensus estimate of an 89 cent loss, still reflects negative earnings.
  • R&D expenses surged to $98.2 million, a 22.3% year-over-year increase driven by scaling clinical pipeline investments and growth in the R&D organization.
  • General and administrative expenses rose 25.1% to $20.4 million due to increased personnel, facility costs, and legal fees associated with being a public company.
  • The upfront payment from the Gilead partnership has been fully recognized, meaning future collaboration revenue will be entirely dependent on milestone payments rather than recurring income.
  • All Q1 collaboration revenues came solely from Gilead (GILD), creating concentration risk as no other significant partner revenue streams were recognized in the quarter.
  • The company currently holds a Zacks Rank #3 (Hold), which is a neutral-to-negative rating compared to competitors like Castle Biosciences that hold a #1 Strong Buy rank.
  • Clinical trial timelines for lead assets KT-621 and KT-579 extend into 2026 and 2027, delaying potential returns on the heavy R&D spend before commercialization.
  • Kymera's cash runway extends to 2029, which is a long-term commitment that exposes the company to valuation pressure if clinical success rates fall short of expectations.
20
Somewhat Bearish -25

Gilead projects $107M Q1 earnings headwind due to recent R&D deals - Seeking Alpha

AI-generated analysis

Gilead Sciences, Inc. (NASDAQ: GILD) announced on April 10, 2026, that it anticipates a $107 million headwind to its first-quarter earnings due to charges associated with recent research and development deals. The pharmaceutical company warned investors that this charge represents an immediate impact on its...

Bullish Signals

  • Management is accelerating M&A with partners like Arcellx for long-term innovation.
  • Gilead's $107M R&D charges are deliberate pipeline investments.
  • Active market engagement demonstrated through expanded deal-making.
  • Acquisitions signal confidence in creating future value.

Bearish Signals

  • Gilead expects $107M Q1 earnings headwind from R&D deal charges.
  • M&A ramp-up will further increase bottom line hit.
  • Transaction costs cut quarterly profitability with no immediate strategic value.